New therapies for ankylosing spondylitis: Etanercept, thalidomide, and pamidronate

Rheumatic Disease Clinics of North America

Volumn 29, Issue 3, 2003, Pages 481-494

  Davis Jr , John C ^a   Huang, Feng ^b   Maksymowych, Walter ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Chinese People's Liberation A G H ^*  (China)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIRHEUMATIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; ETANERCEPT; HLA B27 ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 6; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PREDNISONE; SALAZOSULFAPYRIDINE; THALIDOMIDE; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANKYLOSING SPONDYLITIS; BIRTH DEFECT; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENETIC DISORDER; HEADACHE; HEMATURIA; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NAUSEA; NONHUMAN; PARESTHESIA; PERIPHERAL NEUROPATHY; PHOCOMELIA; PRIORITY JOURNAL; RELAPSE; REVIEW; SERODIAGNOSIS; SPONDYLOARTHROPATHY; TERATOGENICITY; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VOMITING; XEROSTOMIA;

EID: 0042522557     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(03)00028-0     Document Type: Review

References (48)

1. Keffer J, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10(13):4025-31.
2. Crew MD, et al. Transgenic mice expressing a truncated Peromyscus leucopus TNF-alpha gene manifest an arthritis resembling ankylosing spondylitis. J Interferon Cytokine Res 1998;18(4):219-25.
3. Gratacos J, et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994;33(10):927-31.
4. Toussirot E, et al. Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies. Rheumatol Int 1994;13(5):175-80.
5. Braun J, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38(4):499-505.
6. Canete JD, et al. Comparative cytokine gene expression in synovial tissue of early rheumatoid arthritis and seronegative spondyloarthropathies. Br J Rheumatol 1997;36(1):38-42.
7. Mease PJ, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356(9227):385-90.
8. Weinblatt ME. et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340(4):253-9.
9. Moreland LW, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337(3):141-7.
10. Moreland LW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130(6):478-86.
11. Meador R, et al. TNF involvement and anti-tnf therapy of reactive and unclassified arthritis. Clin Exp Rheumatol 2002;20(6 Suppl 28):S130-4.
12. Marzo-Ortega H, et al. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 2001;44(9):2112-7.
13. Gorman JD, Sack KE, Davis Jr. JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346(18):1349-56.
14. Brandt JKA, Listing J, et al. Six months results of a German double-blind placebo controlled, Phase III clinical trial of etanercept in active ankylosing spondylitis. Arthritis and Rheumatism 2002;46:S429.
15. Reiff AHM. Prolonged efficacy of etanercept in refractory juvenile ankylosing spondylitis. Arthritis and Rheumatism 2001;44(S292).
16. Chen TL, et al. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab Dispos 1989;17(4):402-5.
17. Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med 2000;108(6):487-95.
18. Keifer JA, et al. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001;276(25):22382-7.
19. Marriott JB, Muller G, Dalgleish AG. Thalidomide as an emerging immunotherapeutic agent. Immunol Today 1999;20(12):538-40.
20. D'Amato RJ, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91(9):4082-5.
21. Breban M, et al. Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Arthritis Rheum 1999;42(3):580-1.
22. El Hassani SDM, Gombert B, et al. Treatment of severe refractory spondyloarthropathy with thalidomide: results of an open study. Arthritis and Rheumatism 1999;42(S373).
23. Lee L, Lawford R, McNeil HP. The efficacy of thalidomide in severe refractory seronegative spondylarthropathy: comment on the letter by Breban et al. Arthritis Rheum 2001;44(10):2456-8.
24. Huang F, et al. One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum 2002;47(3):249-54.
25. Feltkamp TE, et al. Spondyloarthropathies in eastern Asia. Curr Opin Rheumatol 2001;13(4):285-90.
26. Breban M, et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford) 2002;41(11):1280-5.
27. Corral LG, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163(1):380-6.
28. Bijvoet OL, et al. APD in Paget's disease of bone. Role of the mononuclear phagocyte system? Arthritis Rheum 1980;23(10):1193-204.
29. Cecchini MG, et al. Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. J Bone Miner Res 1987;2(2):135-42.
30. Stevenson PH, Stevenson JR. Cytotoxic and migration inhibitory effects of bisphosphonates on macrophages. Calcif Tissue Int 1986;38(4):227-33.
31. Sansoni P, et al. Inhibition of antigen-presenting cell function by alendronate in vitro. J Bone Miner Res 1995;10(11):1719-25.
32. Pennanen N, et al. Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro. Pharm Res 1995;12(6):916-22.
33. Leyvraz S, et al. Pharmacokinetics of pamidronate in patients with bone metastases. J Natl Cancer Inst 1992;84(10):788-92.
34. Sato M, Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 1990;5(1):31-40.
35. Barbier A, et al. Studies on the chronic phase of adjuvant arthritis: effect of SR 41319, a new diphosphonate. Ann Rheum Dis 1986;45(1):67-74.
36. Francis MD, Hovancik K, Boyce RW. NE-58095: a diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. Int J Tissue React 1989;11(5):239-52.
37. Markusse HM, Lafeber GJ, Breedveld FC. Bisphosphonates in collagen arthritis. Rheumatol Int 1990;9(6):281-3.
38. Redlich K, et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002;46(3):785-92.
39. Lipton A, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88(5):1082-90.
40. Varenna M, et al. Intravenous pamidronate in the treatment of transient osteoporosis of the hip. Bone 2002;31(1):96-101.
41. Maksymowych WP, et al. An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol 1998;25(4):714-7.
42. Maksymowych WP, et al. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol 2001;28(1):144-55.
43. Collantes-Estevez E, Munoz-Villanueva MC. Clinical improvement of refractory ankylosing spondylitis by pulse intravenous pamidronate therapy. Ann Rheum Dis, in press.
44. Adami S, et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987;41(6):326-31.
45. Maksymowych WP, et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002;46(3): 766-73.
46. Pavy S, Marks S, Calin A. Approaching the concept of minimum clinically important difference with the bath ankylosing spondylitis indies. Arthritis and Rheumatism 2001;44(Suppl):s295.
47. Lehman TJ, Striegel KH, Onel KB. Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis. J Pediatr 2002;140(1):125-7.
48. Van Offel JF, et al. Effect of bisphosphonates on viability, proliferation, and dexamethasone-induced apoptosis of articular chondrocytes. Ann Rheum Dis 2002;61(10):925-8.